Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report

A. U. Buzdar, G. R. Blumenschein, J. U. Gutterman, C. K. Tashima, G. N. Hortobagyi, T. L. Smith, L. T. Campos, W. L. Wheeler, Evan M Hersh, E. J. Freireich, E. A. Gehan

Research output: Contribution to journalArticlepeer-review

Abstract

222 patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease.

Original languageEnglish (US)
Pages (from-to)1509-1513
Number of pages5
JournalJournal of the American Medical Association
Volume242
Issue number14
DOIs
StatePublished - 1979
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report'. Together they form a unique fingerprint.

Cite this